- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| COGNITION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Do | Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update | 51 | GlobeNewswire (Europe) | PURCHASE, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the "Company"... ► Artikel lesen | |
| Do | COGNITION THERAPEUTICS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 13.07. | Cognition Therapeutics, Inc.: Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit | 1 | GlobeNewswire (USA) | ||
| 01.07. | H.C. Wainwright reiterates Cognition Therapeutics stock rating on FDA alignment | 2 | Investing.com | ||
| 24.06. | Cognition Therapeutics, Inc.: Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes | 394 | GlobeNewswire (Europe) | - Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease -- Company Developing NPI as a Measure of DLB Psychosis - PURCHASE, N.Y., June 24, 2026 (GLOBE... ► Artikel lesen | |
| 22.06. | H.C. Wainwright reiterates Cognition Therapeutics stock rating on patent news | 1 | Investing.com | ||
| 18.06. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 3 | SEC Filings | ||
| 16.06. | Cognition Therapeutics, Inc.: Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045 | 443 | GlobeNewswire (Europe) | PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative... ► Artikel lesen | |
| 04.06. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 21.05. | Cognition Therapeutics, Inc.: Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis | 430 | GlobeNewswire (Europe) | - Positive Discussion on Path Forward for Registrational Program - PURCHASE, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage... ► Artikel lesen | |
| 21.05. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 4 | SEC Filings | ||
| 14.05. | Cognition Therapeutics receives donation to extend DLB program | 2 | Investing.com | ||
| 14.05. | Cognition Therapeutics, Inc.: Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies | 1 | GlobeNewswire (USA) | ||
| 08.05. | COGNITION THERAPEUTICS INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.05. | Cognition Therapeutics GAAP EPS of -$0.05 beats by $0.02 | 5 | Seeking Alpha | ||
| 07.05. | Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update | 846 | GlobeNewswire (Europe) | Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to informregistrational plans for zervimesine in DLB psychosis PURCHASE, N.Y., May 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics... ► Artikel lesen | |
| 07.05. | COGNITION THERAPEUTICS INC - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | Cognition Therapeutics plant entscheidende Studie für Demenz-Wirkstoff | 3 | Investing.com Deutsch | ||
| 31.03. | Cognition Therapeutics plans late-stage trial for dementia drug | 1 | Investing.com | ||
| 31.03. | Cognition Therapeutics, Inc.: Cognition Therapeutics CEO Issues Letter to Shareholders | 340 | GlobeNewswire (Europe) | Advancing Zervimesine (CT1812) towards late-stage trials for dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second half of 2027 PURCHASE... ► Artikel lesen |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,75 | +2,11 % | BioNTech SE und Emyria Limited: Wenn schlafende Biotech-Riesen erwachen und datenstarke Plattformen den Markt erobern | ||
| AMGEN | 350,55 | -0,26 % | Ihre wichtigsten Termine: Q2-Updates von SpaceX, Bayer, Biontech, Spotify, Pfizer, Continental, Merck & Co | © Foto: Dall-EGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 05:00 Uhr, Großbritannien:... ► Artikel lesen | |
| NOVAVAX | 6,770 | +0,74 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| BIOGEN | 180,20 | +0,65 % | Biogen Inc.: Biogen Completes Acquisition of RayThera Inc. | Lead program now in Phase 1 developmentCAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately... ► Artikel lesen | |
| CLINUVEL | 5,720 | +1,92 % | Clinuvel Pharmaceuticals Limited: CLINUVEL implements strategic reorganisation to refocus on U.S. markets | MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced a strategic reorganisation of its operations and workforce... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,300 | +1,38 % | Viking Therapeutics, BioNxt Solutions, Bausch Health - Studienerfolg entfacht neue Fantasie | Die Pharmaindustrie steht vor einer neuen Wachstumsphase. Milliarden fließen in innovative Therapien, moderne Arzneimitteltechnologien und die Weiterentwicklung etablierter Medikamente. Besonders dynamisch... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,060 | +3,07 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S.... ► Artikel lesen | |
| TEMPUS AI | 40,440 | +1,11 % | BTIG cuts Tempus AI stock price target to $70 on model update | ||
| EDITAS MEDICINE | 2,470 | -2,37 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,140 | +0,79 % | Biocryst outlines $690M-$715M 2026 total revenue guidance with operating costs at $420M-$440M | ||
| BIOMARIN PHARMACEUTICAL | 55,16 | +6,90 % | BioMarin Pharmaceutical Inc.: BioMarin Reports Second Quarter 2026 Financial and Operating Results | Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million
Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,272 | -3,20 % | Der Weg zur Klinik: Wie Finanzierung Biotech-Erfolge ermöglicht | ||
| EXELIXIS | 46,005 | +1,53 % | Exelixis outlines zanza CRC launch plans as 2026 revenue guidance midpoint is lowered by $50M | ||
| SAREPTA THERAPEUTICS | 14,720 | +1,10 % | Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,039 | +2,77 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen |
COGNITION THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,88 % bei einem Aktienkurs von 1,120 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COGNITION THERAPEUTICS INC finden Sie auf Wallstreet Online.